Entries tagged "Pfizer Inc"
Back in August 2007, The Deal's Alex Lash outlined the reasons why Pfizer Inc. should shell out some major cash to purchase Wyeth. And now less than two years later -- voila! -- the two pharma giants are set to merge in a $68 billion deal. ...
For those of you thinking that the Pfizer Inc. deal for Wyeth means that Wall Street or investment banking is back, well, au contraire. There aren't many companies with the recession-resistant cash flow of Pfizer, and with its need to buy. Yes, it's a good sign that banks are willing to finance the big deal, but it shows only that they're not dead yet, not that animal spirits are loose. Besides, if you're getting heat from Washington about lending, a deal like this may be even better, meaning safer, than InBev SA's acquisition of Anheuser-Busch Cos. or Mars Inc.'s purchase...
Speculation about a Pfizer Inc. deal for Wyeth, first reported in Friday's Wall Street Journal, raises an age-old question that applies to more than just the pharmaceutical industry: size, its merits and demerits. Over the past decade or so, Pfizer has steadily built itself through acquisitions into a behemoth, and the Wyeth deal would push it to $75 billion in revenues. The argument for consolidation and great size has several parts, some obvious, some not. ...
The 27th J.P. Morgan healthcare conference kicks off Monday morning in San Francisco, one of the industry's top dealmaking venues of the year centered in and, for the multitude of parties and meetings, around the city's storied St. Francis hotel (pictured). ...
